In the Pipeline

In the Pipeline for late 2018/early 2019

Several new compounds have currently been in development for a late 2018/early 2019 release.

These Include

• GW0742 / GW610742 – PPARδ/β agonist

PPAR activation in a similar modality to GW-501516

• CP-424,391 (Capromorelin) –  Growth hormone secretagogue / ghrelin mimetic

Similar secretagogue to MK677

• GSK4112 – Rev-erbα agonist

Rev-ErbA gene activation in a different modality to SR9009 and SR9011

• Pure form, high purity CBD Isolate – CB agonist

99% purity CBD (with no other terpenes) to impart the anti inflammatory effects from CB receptor activation